Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes.

Johänning J, Kröner P, Thomas M, Zanger UM, Nörenberg A, Eichelbaum M, Schwab M, Brauch H, Schroth W, Mürdter TE.

Arch Toxicol. 2018 Mar;92(3):1099-1112. doi: 10.1007/s00204-017-2147-y. Epub 2017 Dec 28.

2.

Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison.

Leuthold P, Schaeffeler E, Winter S, Büttner F, Hofmann U, Mürdter TE, Rausch S, Sonntag D, Wahrheit J, Fend F, Hennenlotter J, Bedke J, Schwab M, Haag M.

J Proteome Res. 2017 Feb 3;16(2):933-944. doi: 10.1021/acs.jproteome.6b00875. Epub 2017 Jan 12.

PMID:
27992229
3.

Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest.

Schaaf L, Schwab M, Ulmer C, Heine S, Mürdter TE, Schmid JO, Sauer G, Aulitzky WE, van der Kuip H.

Cancer Res. 2016 May 15;76(10):2868-75. doi: 10.1158/0008-5472.CAN-15-2908. Epub 2016 Mar 24.

4.

A Temperature of 40 °C Appears to be a Critical Threshold for Potentiating Cytotoxic Chemotherapy In Vitro and in Peritoneal Carcinomatosis Patients Undergoing HIPEC.

Schaaf L, van der Kuip H, Zopf W, Winter S, Münch M, Mürdter TE, Thon KP, Steurer W, Aulitzky WE, Ulmer C.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S758-65. doi: 10.1245/s10434-015-4853-0. Epub 2015 Sep 8.

PMID:
26350370
5.

Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS.

Johänning J, Heinkele G, Precht JC, Brauch H, Eichelbaum M, Schwab M, Schroth W, Mürdter TE.

Anal Bioanal Chem. 2015 Sep;407(24):7497-502. doi: 10.1007/s00216-015-8907-8. Epub 2015 Jul 25.

PMID:
26206706
6.

Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na(+)-taurocholate cotransporting polypeptide inhibitor.

Haag M, Hofmann U, Mürdter TE, Heinkele G, Leuthold P, Blank A, Haefeli WE, Alexandrov A, Urban S, Schwab M.

Anal Bioanal Chem. 2015 Sep;407(22):6815-25. doi: 10.1007/s00216-015-8853-5. Epub 2015 Jul 5.

PMID:
26143062
7.

A new [2H]-labelled α-trichloroimidate glucuronic ester for the synthesis of deuterated drug conjugates.

Heinkele G, Geditz MC, Ganchev B, Kerb R, Hofmann U, Mürdter TE.

J Labelled Comp Radiopharm. 2014 Oct;57(12):699-703. doi: 10.1002/jlcr.3243. Epub 2014 Oct 22.

PMID:
25339577
8.

Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.

Maximov PY, McDaniel RE, Fernandes DJ, Korostyshevskiy VR, Bhatta P, Mürdter TE, Flockhart DA, Jordan VC.

Br J Pharmacol. 2014 Dec;171(24):5624-35. doi: 10.1111/bph.12864.

9.

Reply to A.-S. Dieudonné et al and J.M. Rae et al.

Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M.

J Clin Oncol. 2013 Jul 20;31(21):2755-6. No abstract available.

PMID:
24040664
10.

The letrozole phase 1 metabolite carbinol as a novel probe drug for UGT2B7.

Precht JC, Schroth W, Klein K, Brauch H, Krynetskiy E, Schwab M, Mürdter TE.

Drug Metab Dispos. 2013 Nov;41(11):1906-13. doi: 10.1124/dmd.113.053405. Epub 2013 Aug 21.

PMID:
23965986
11.

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M.

J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22. No abstract available.

12.

Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin.

Schmid JO, Dong M, Haubeiss S, Friedel G, Bode S, Grabner A, Ott G, Mürdter TE, Oren M, Aulitzky WE, van der Kuip H.

Cancer Res. 2012 Nov 15;72(22):5824-32. doi: 10.1158/0008-5472.CAN-12-1201. Epub 2012 Sep 7.

13.

Pulmonary delivery and tissue distribution of aerosolized antisense 2'-O-Methyl RNA containing nanoplexes in the isolated perfused and ventilated rat lung.

Dong M, Mürdter TE, Philippi C, Loretz B, Schaefer UF, Lehr CM, Schwab M, Ammon-Treiber S.

Eur J Pharm Biopharm. 2012 Aug;81(3):478-85. doi: 10.1016/j.ejpb.2012.04.022. Epub 2012 May 4.

PMID:
22565122
14.

TKTL-1 expression in lung cancer.

Fritz P, Coy JF, Mürdter TE, Ott G, Alscher MD, Friedel G.

Pathol Res Pract. 2012 Apr 15;208(4):203-9. doi: 10.1016/j.prp.2012.01.007. Epub 2012 Mar 24.

PMID:
22445516
15.

Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS.

Precht JC, Ganchev B, Heinkele G, Brauch H, Schwab M, Mürdter TE.

Anal Bioanal Chem. 2012 Apr;403(1):301-8. doi: 10.1007/s00216-012-5813-1. Epub 2012 Feb 25.

PMID:
22367241
16.

Treatment of lung cancer via telomerase inhibition: self-assembled nanoplexes versus polymeric nanoparticles as vectors for 2'-O-Methyl-RNA.

Nafee N, Schneider M, Friebel K, Dong M, Schaefer UF, Mürdter TE, Lehr CM.

Eur J Pharm Biopharm. 2012 Apr;80(3):478-89. doi: 10.1016/j.ejpb.2011.11.019. Epub 2011 Dec 17.

PMID:
22198416
17.

Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.

Mürdter TE, Kerb R, Turpeinen M, Schroth W, Ganchev B, Böhmer GM, Igel S, Schaeffeler E, Zanger U, Brauch H, Schwab M.

Hum Mol Genet. 2012 Mar 1;21(5):1145-54. doi: 10.1093/hmg/ddr543. Epub 2011 Nov 22.

PMID:
22108178
18.

Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense 2'-O-methyl-RNA.

Dong M, Philippi C, Loretz B, Nafee N, Schaefer UF, Friedel G, Ammon-Treiber S, Griese EU, Lehr CM, Klotz U, Mürdter TE.

Int J Pharm. 2011 Oct 31;419(1-2):33-42. doi: 10.1016/j.ijpharm.2011.07.009. Epub 2011 Jul 18.

PMID:
21782910
19.

Quantification of clomiphene metabolite isomers in human plasma by rapid-resolution liquid chromatography-electrospray ionization-tandem mass spectrometry.

Ganchev B, Heinkele G, Kerb R, Schwab M, Mürdter TE.

Anal Bioanal Chem. 2011 Jul;400(10):3429-41. doi: 10.1007/s00216-011-5045-9. Epub 2011 May 1.

PMID:
21533795
20.

Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.

Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T; German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H.

Clin Pharmacol Ther. 2011 May;89(5):708-17. doi: 10.1038/clpt.2011.27. Epub 2011 Mar 30. Erratum in: Clin Pharmacol Ther. 2012 Jun;91(6):1087.

PMID:
21451508
21.

Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts.

Haubeiss S, Schmid JO, Mürdter TE, Sonnenberg M, Friedel G, van der Kuip H, Aulitzky WE.

Mol Cancer. 2010 Jun 27;9:168. doi: 10.1186/1476-4598-9-168.

22.

Telomeres and telomerase as novel drug targets: reflections on the 2009 Nobel Prize in Physiology or Medicine.

Dong M, Mürdter TE, Klotz U.

Eur J Clin Pharmacol. 2010 Jan;66(1):1-3. doi: 10.1007/s00228-009-0758-9. Epub 2009 Nov 21. No abstract available.

PMID:
19936723
23.

Nanoparticle mediated delivery of 2'-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells.

Beisner J, Dong M, Taetz S, Nafee N, Griese EU, Schaefer U, Lehr CM, Klotz U, Mürdter TE.

Lung Cancer. 2010 Jun;68(3):346-54. doi: 10.1016/j.lungcan.2009.07.010. Epub 2009 Aug 19.

PMID:
19695733
24.

Pharmacogenomics of tamoxifen therapy.

Brauch H, Mürdter TE, Eichelbaum M, Schwab M.

Clin Chem. 2009 Oct;55(10):1770-82. doi: 10.1373/clinchem.2008.121756. Epub 2009 Jul 2. Review.

25.

Fate of the antibiotic sulfamethoxazole and its two major human metabolites in a water sediment test.

Radke M, Lauwigi C, Heinkele G, Mürdter TE, Letzel M.

Environ Sci Technol. 2009 May 1;43(9):3135-41.

PMID:
19534125
26.

Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.

Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Mürdter TE, Aulitzky WE.

BMC Cancer. 2008 Dec 11;8:364. doi: 10.1186/1471-2407-8-364.

27.

Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2'-O-methyl-RNA.

Beisner J, Dong M, Taetz S, Piotrowska K, Kleideiter E, Friedel G, Schaefer U, Lehr CM, Klotz U, Mürdter TE.

J Pharm Sci. 2009 May;98(5):1765-74. doi: 10.1002/jps.21553.

PMID:
18803262
28.

The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2'-O-methyl-RNA directed against telomerase in lung cancer cells.

Taetz S, Nafee N, Beisner J, Piotrowska K, Baldes C, Mürdter TE, Huwer H, Schneider M, Schaefer UF, Klotz U, Lehr CM.

Eur J Pharm Biopharm. 2009 Jun;72(2):358-69. doi: 10.1016/j.ejpb.2008.07.011. Epub 2008 Jul 27.

PMID:
18703137
29.

Decomposition of the telomere-targeting agent BRACO19 in physiological media results in products with decreased inhibitory potential.

Taetz S, Mürdter TE, Zapp J, Boettcher S, Baldes C, Kleideiter E, Piotrowska K, Schaefer UF, Klotz U, Lehr CM.

Int J Pharm. 2008 Jun 5;357(1-2):6-14. doi: 10.1016/j.ijpharm.2008.01.026. Epub 2008 Jan 20.

PMID:
18313869
30.

TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.

Buck MB, Coller JK, Mürdter TE, Eichelbaum M, Knabbe C.

Breast Cancer Res Treat. 2008 Jan;107(1):15-24. Epub 2007 Feb 15.

PMID:
18043895
31.

Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.

Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, Dörje F, Mürdter TE, Ackermann A, Dormann H, Gassmann KG, Hahn EG, Zierhut S, Brune K, Fromm MF.

Clin Pharmacokinet. 2007;46(12):1039-49.

PMID:
18027988
33.

Biopharmaceutical characterization of the telomerase inhibitor BRACO19.

Taetz S, Baldes C, Mürdter TE, Kleideiter E, Piotrowska K, Bock U, Haltner-Ukomadu E, Mueller J, Huwer H, Schaefer UF, Klotz U, Lehr CM.

Pharm Res. 2006 May;23(5):1031-7. Epub 2006 May 4.

PMID:
16715394
34.

Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.

Becquemont L, Glaeser H, Drescher S, Hitzl M, Simon N, Murdter TE, Heinkele G, Hofmann U, Schaefer C, Burk O, Verstuyft C, Eichelbaum M, Fromm MF.

Clin Pharmacol Ther. 2006 May;79(5):449-60. Epub 2006 Apr 11.

PMID:
16678547
35.

Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.

van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE.

BMC Cancer. 2006 Apr 7;6:86.

36.

Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors.

Piotrowska K, Kleideiter E, Mürdter TE, Taetz S, Baldes C, Schaefer U, Lehr CM, Klotz U.

Lab Invest. 2005 Dec;85(12):1565-9.

37.

Induction of metallothionein in proximal tubular cells by zinc and its potential as an endogenous antioxidant.

Alscher DM, Braun N, Biegger D, Stuelten C, Gawronski K, Mürdter TE, Kuhlmann U, Fritz P.

Kidney Blood Press Res. 2005;28(3):127-33. Epub 2005 Apr 5.

38.

Impact of mistletoe lectin binding in breast cancer.

Fritz P, Dippon J, Kierschke T, Siegle I, Möhring A, Moisa A, Mürdter TE.

Anticancer Res. 2004 Mar-Apr;24(2C):1187-92.

39.

Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.

Coller JK, Krebsfaenger N, Klein K, Wolbold R, Nüssler A, Neuhaus P, Zanger UM, Eichelbaum M, Mürdter TE.

Br J Clin Pharmacol. 2004 Jan;57(1):105-11.

40.

Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.

Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger UM.

J Pharmacol Exp Ther. 2004 Jan;308(1):189-97. Epub 2003 Oct 16.

PMID:
14563790
41.

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mürdter TE, Roots I, Brockmöller J.

Pharmacogenetics. 2003 Oct;13(10):619-26.

PMID:
14515060
42.

V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans.

Krebsfaenger N, Mürdter TE, Zanger UM, Eichelbaum MF, Doehmer J.

ALTEX. 2003;20(3):143-54.

43.

Population pharmacokinetics of oral busulfan in children.

Schiltmeyer B, Klingebiel T, Schwab M, Mürdter TE, Ritter CA, Jenke A, Ehninger G, Gruhn B, Würthwein G, Boos J, Hempel G.

Cancer Chemother Pharmacol. 2003 Sep;52(3):209-16. Epub 2003 Jun 17.

PMID:
12811512
44.

Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography-tandem mass spectrometry.

Hofmann U, Schwab M, Seefried S, Marx C, Zanger UM, Eichelbaum M, Mürdter TE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):371-80.

PMID:
12798197
45.

Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.

Brenner SS, Herrlinger C, Dilger K, Mürdter TE, Hofmann U, Marx C, Klotz U.

Clin Pharmacokinet. 2003;42(3):283-92.

PMID:
12603175
46.

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.

Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, Nüssler A, Neuhaus P, Zanger UM, Eichelbaum M, Mürdter TE.

Br J Clin Pharmacol. 2002 Aug;54(2):157-67.

47.

Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus.

Sperker B, Mürdter TE, Backman JT, Fritz P, Kroemer HK.

Life Sci. 2002 Aug 16;71(13):1547-57.

PMID:
12127909
48.

Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation.

Bredschneider M, Klein K, Mürdter TE, Marx C, Eichelbaum M, Nüssler AK, Neuhaus P, Zanger UM, Schwab M.

Clin Pharmacol Ther. 2002 Jun;71(6):479-87.

PMID:
12087351
49.

Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase.

Mürdter TE, Friedel G, Backman JT, McClellan M, Schick M, Gerken M, Bosslet K, Fritz P, Toomes H, Kroemer HK, Sperker B.

J Pharmacol Exp Ther. 2002 Apr;301(1):223-8.

PMID:
11907177
50.

Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection.

Schönberger F, Heinkele G, Mürdter TE, Brenner S, Klotz U, Hofmann U.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 5;768(2):255-60.

PMID:
11888053

Supplemental Content

Loading ...
Support Center